The Angels Initiative
The Angels Initiative helps hospitals around the world become ‘stroke-ready’ so that stroke patients can be treated as quickly and effectively as possible.
Search
Leticia develops product medical strategies
Leticia develops product medical strategies at Boehringer Ingelheim. For more talent insights, visit our Careers Page.
Positive results Diabetic Macular Ischemia treatment
HORNBILL Phase I/II study shows positive results for potentially first ever Diabetic Macular Ischemia treatment
Phase 1 start of treatment for Geographic Atrophy patients
Boehringer initiates Phase 1 evaluation of BI 771716 a treatment for preserving vision of people living with geographic atrophy (GA)
Striving to revolutionize mental health research
World Mental Health Day: Through a precision psychiatry approach and rich pipeline, we are committed to transforming the mental health landscape.
Resizing our Carbon Footprint
The ecological balance of the world is at a tipping point.
Vegetablehash video
This colourful, delicious breakfast is a great way to start the day. Watch this video to learn how to make it.
Improving Access to Stroke Care
Angels Initiative named Best Practice example by the Access to Medicine Index
Combination Therapy
It’s the smart combination of our cancer cell-directed and immuno-oncology approaches that may offer the greatest benefit for people living with cancer.
Patient voices Augustos story
Hear from patients and families on how atrial fibrillation (AF), deep vein thrombosis (DVT) and pulmonary embolism (PE) have affected their lives
Patient voices Eves story
Eve’s Story: Hear from patients and families on how atrial fibrillation (AF), deep vein thrombosis (DVT) and pulmonary embolism (PE) have affected their lives
Patient voices Ulrichs story
Ulrich’s Story: Hear from patients and families on how atrial fibrillation (AF), deep vein thrombosis (DVT) and pulmonary embolism (PE) have affected their lives
Tackling NCDs through innovation AND collaboration
Non-communicable diseases are a significant medical, humanitarian and socio-economic issue. Rapid innovation and holistic approaches help us tackle them
Partnering pet therapeutics
Learn more about our research focus and our most recent partnerships regarding pet therapeutics.
TCO patient podcasts
From clinical trials to living with cancer, hear patient perspectives on different cancer topics in this podcast series.
clinical_collaboration_with_Mirati
Boehringer Ingelheim and Mirati are teaming up in a clinical collaboration to evaluate the combination of the SOS1::pan-KRAS and the selective G12C inhibitor.
Welcome to Innovation at Boehringer Ingelheim
Watch our video and find out more about innovation at Boehringer Ingelheim.
Expert Advice from Dr Clare Shaw
Consultant oncology dietitian Dr Clare Shaw shares her advice on some of the most common cancer nutrition misunderstandings.
Brigimadlin (BI 907828)
Brigimadlin BI 907828
Combatting Appetite Loss
Discover tips on how to combat appetite loss from Taking Cancer On Through Flavour
BI 764532
DLL3/CD3 T-cell engager
History of Cats
From the African wildcat to the domesticated house cat of today, the fascinating journey and history of the cat touches almost all corners of the world.
empulse-trial-benefit-acute-heart-failure
Empagliflozin provided a significant clinical benefit in adults stabilized in hospital following acute heart failure in EMPULSE Phase III trial
BI increases commitments to sustainable development
At the World Health Summit 2021, Boehringer Ingelheim announces updates to its strategic approach to sustainable development
Zongertinib (BI 1810631)
Zongertinib (BI 1810631)